Takeda, Seattle Genetics Report Data from Phase 3 ALCANZA Trial of ADCETRIS for CD30-Expressing Cutaneous T-Cell Lymphoma: Met Primary Endpoint, Showed Highly Statistically Significant Improvement
Paul Quintaro